<scp>Real‐World</scp> nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma-Reference-Cited by-同舟云学术

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma

Published:2022-07-25 Issue:3 Volume:12 Page:2378-2388
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Samlowski Wolfram¹²^ORCID,Robert Nicholas J.³,Chen Liwei³,Schenkel Brad⁴,Davis Catherine⁴,Moshyk Andriy⁴,Kotapati Srividya⁴,Poretta Tayla⁴,Weber Jeffrey S.⁵

Affiliation:

1. Comprehensive Cancer Centers of Nevada and University of Nevada Las Vegas Kirkorian School of Medicine Las Vegas Nevada USA

2. University of Nevada School of Medicine Reno Nevada USA

3. McKesson Life Sciences The Woodlands Texas USA

4. Bristol Myers Squibb Princeton New Jersey USA

5. Perlmutter Cancer Center NYU School of Medicine New York New York USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5061

Reference15 articles.

1. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

2. US Food and Drug Administration.FDA grants regular approval to nivolumab for adjuvant treatment of melanoma. [internet].2017. [cited January 17 2022]. Available from:.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐regular‐approval‐nivolumab‐adjuvant‐treatment‐melanoma

3. Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

4. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden;Journal for ImmunoTherapy of Cancer;2024-08

2. Evaluation of safety outcomes between nivolumab regimens with differing dosing patterns;Journal of Oncology Pharmacy Practice;2024-07-23

3. Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses;Journal of Gastrointestinal Cancer;2024-07-15

4. Efficacy and safety of salvage-line nivolumab monotherapy for advanced esophageal squamous cell carcinoma: Comparison of 240 mg versus 480 mg doses;2024-05-02

5. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma;Melanoma Research;2024-03-15